ODM-208

PreclinicalSmall molecule

Orion Corporation, Orion Pharma

ODM-208 is one of 6 small molecule programs targeting Prostate Cancer Metastatic. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate Cancer MetastaticActive, not recruiting

Prostate Cancer MetastaticPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Prostate Cancer Metastatic

#DrugCompanyPhaseTrials

Zytiga

Johnson & Johnson

Phase 3

2 2

Fludara

Sanofi

Preclinical

1 3

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 4

Cytoxan

BBaxter Healthcare Corporation

Preclinical

1 5

Adi-212

AAdicet Therapeutics

Preclinical

1 6

ODM-208

Orion Corporation, Orion Pharma

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer Metastatic1 trial

Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

Active, not recruiting· Orion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma·Preclinical·NCT03436485·204 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ODM-208. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ODM-208 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ODM-208. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Orion Corporation, Orion Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Orion Corporation, Orion Pharma

ODM-208

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer Metastatic1 trial

References

Drug Info

Quick Facts

Related News